Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04396626 · ClinicalTrials.gov registry record
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 975
- Enrollment target
NCT04396626 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 975 participants.
The verdict
NCT04396626 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 975 participants
- Enrollment target
Study Summary
This is a retrospective, observational study that will document the treatment patterns and clinical outcomes of patients diagnosed with HR+/HER2- A/MBC who received CDK4/6i combination therapy with aromatase inhibitors (AI) as the initial endocrine-based therapy in the A/MBC setting.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2020-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04396626
The ClinicalTrials.gov registry entry for NCT04396626 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 975 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04396626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04396626 about?
NCT04396626 is a clinical study titled "HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes". This is a retrospective, observational study that will document the treatment patterns and clinical outcomes of patients diagnosed with HR+/HER2- A/MBC who received CDK4/6i combination therapy with aromatase inhibitors (AI) as the initial endocrine-based therapy in the A/MBC setting.
What is the current status of trial NCT04396626?
This trial is currently terminated. The enrollment target is 975 participants. The study started on 2019-11-18. Estimated completion is 2020-05-31.
Who is sponsoring clinical trial NCT04396626?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.